ArticleThe Journal of clinical investigation1999
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 132 citations in OpenAlex.
- Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.Journal of gastroenterology · 2009Trial
- Revisiting Cryptocyanine Dye, NK-4, as an Old and New Drug: Review and Future Perspectives.International journal of molecular sciences · 2023Review
- Mutations and methods of analysis of mutations in Hepatitis B virus.AIMS microbiology · 2020Review
- Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B.Infectious diseases and therapy · 2016Article
- Article
- Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.Digestive diseases and sciences · 2008Article
- Current status of antiviral therapy for hepatitis B.Therapeutic advances in gastroenterology · 2008Article
- In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.Journal of virology · 2007Article
- Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.Journal of virology · 2004Article
- Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.Digestive diseases and sciences · 2004Article
- Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.Antimicrobial agents and chemotherapy · 2003Article
- Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.Antimicrobial agents and chemotherapy · 2002Article
- Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.Antimicrobial agents and chemotherapy · 2002Article
- Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.Antimicrobial agents and chemotherapy · 2002Article
- In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Antimicrobial agents and chemotherapy · 2001Article
- Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.Antimicrobial agents and chemotherapy · 2001Article
- Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).Journal of virology · 2001Article
- Current Options for the Therapy of Chronic Hepatitis B Infection.Current infectious disease reports · 2001Article
- The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.The Journal of clinical investigation · 2001Article
- Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.Antimicrobial agents and chemotherapy · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The emergence of resistant hepatitis B virus (HBV), with mutations in the YMDD motif of the polymerase gene after treatment with lamivudine, is becoming an important clinical problem. In this study, susceptibility of wild-type and lamivudine-resistant HBV M552I, M552V, and L528M/M552V mutants to other reverse transcriptase inhibitors was investigated by transient transfection of full-length HBV DNA into human hepatoma cells. HBV DNA replication was monitored by Southern blot hybridization, which showed the presence of a single-stranded band (representative of the HBV replicative intermediates) in the drug-free, wild-type HBV-transfected cells. This band was diminished in the samples of wild-type HBV DNA treated with either lamivudine, adefovir, or lobucavir. The band intensities from the lamivudine-resistant mutants were not decreased by treatment with lamivudine, but were decreased by the treatments with adefovir or lobucavir. In contrast, penciclovir and nevirapine did not diminish the intensity of the single-stranded band of wild-type HBV or the lamivudine-resistant mutants. These results demonstrate that lamivudine-resistant HBV is susceptible to adefovir and lobucavir. Lamivudine-resistant HBV should be treated with adefovir or lobucavir, and combination therapy with lamivudine and adefovir/lobucavir may prevent the emergence of lamivudine-resistant HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.